Back to articles

A brighter tomorrow? New anemia treatment strategies on the horizon


Several emerging strategies for managing anemia in patients with chronic kidney disease (CKD) offer potential advantages over erythropoiesis stimulating agents (ESAs) such as epoetin alfa (Epogen—Amgen; Procrit—Ortho Biotech) and darbepoetin alfa (Aranesp—Amgen), according to a recent review article. Advantages and disadvantages of promising agents, including the recently approved peginesatide (Omontys—Affymax), are discussed.


Macdougall I. New anemia therapies: translating novel strategies from bench to bedside. Am J Kidney Dis. 2012;59:444–51.